GEMINI | Jotup

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on:

Tuesday, April 2, 2024

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points:

OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
Lead author: Julio Echegoyen, MD, PhD
Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on:

Wednesday, February 7, 2024

Antigen, Massachusetts General Hospital, Immunotherapy, Research, GEA, Stomach cancer, Patient, Safety, Bone marrow, Dana–Farber Cancer Institute, DRS, Cancer, Doctor of Philosophy, De Gregorio, GEMINI, Pharmaceutical industry

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points:

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
"We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

Grant Awarded to Develop Gastric Cancer Vaccine to Prevent Relapse After Surgery

Retrieved on:

Thursday, February 1, 2024

Immune system, Research, Stomach cancer, Patient, Safety, Diagnosis, Bone marrow, Incidence, Disease, Harvard Medical School, B cell, Vaccination, Stomach, Neoplasm, Cancer, De Gregorio, GEMINI, Vaccine

Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.

Key Points:

Gastric cancer is the fourth leading cause of cancer mortality worldwide with mean life expectancy after standard therapy of 12 to 15 months.
Avigan and his team hypothesize that a cancer vaccine targeting gastric cancer can help to train the immune system to eradicate tumor cells throughout the body and prevent disease relapse after surgery.
In the present study, they will examine whether designing this type of vaccine against gastric cancer will be effective in generating an immune response directed against gastric cancer cells.
They will use a novel approach to generating the vaccine to culture cancer cells outside the body as a part of vaccine production.

Grant Awarded to Identify New Druggable Targets in Gastroesophageal Cancer

Retrieved on:

Tuesday, January 30, 2024

Dana–Farber Cancer Institute, Patient, Stomach cancer, GEMINI, Research, Knowledge, Cancer, Immunotherapy, De Gregorio, Drug development, Doctor of Philosophy, Therapy, Pharmaceutical industry

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.

Key Points:

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative ( GEMINI ) has awarded $200,000 to Eric S. Fischer, PhD, of Dana-Farber Cancer Institute to discover new protein degradation targets in gastroesophageal cancer.
This approach allows the expansion of the scope of targeted therapies beyond conventionally druggable targets such as kinases and holds tremendous promise for new therapies.
Patients continue to face poor prognoses following gastric and esophageal cancer diagnoses due to their chemo-resistant behavior and ability to metastasize.
Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

Retrieved on:

Monday, December 11, 2023

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD). These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.

Key Points:

New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced new data that treatment with Auvelity® (dextromethorphan-bupropion) was associated with improvement in quality of life outcomes in broad populations of depression patients in the EVOLVE open-label trial in major depressive disorder (MDD).
These new data were presented at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting, held in Tampa, Florida, from Dec. 3-6, 2023.
An evaluation of interest and activity levels of individuals with MDD following treatment with Auvelity in a pooled post-hoc analysis of the placebo-controlled GEMINI and active-controlled ASCEND studies, and an analysis of potential withdrawal symptoms following discontinuation of Auvelity treatment in the GEMINI trial were also presented.
“Depression exacts an extraordinary impact on affected individuals especially by impairing enjoyment in activities and role function,” said Roger McIntyre, MD, FRCPC, Professor of Psychiatry and Pharmacology at the University of Toronto and lead author.

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Retrieved on:

Friday, December 8, 2023

IOP, OMNI, GEMINI, Ophthalmology, ANSI, Intraocular pressure, Patient, Safety, Pharmaceutical industry

MENLO PARK, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced the acceptance for publication in Clinical Ophthalmology of the prospective, multi-center, three-year GEMINI 2 trial with long-term clinical outcomes for patients treated with the OMNI® Surgical System technology (“OMNI”). Publication is currently expected by December 31, 2023.

Key Points:

GEMINI 2, a prospective, multi-center, medication washout trial designed to obtain 36-month follow-up for patients treated in the original 12-month GEMINI trial, has been completed.
Favorable results demonstrate sustained and clinically significant intraocular pressure (“IOP”) reduction of greater than 20% and clinically significant IOP lowering medication reduction at 36 months.
The prospective 3-year clinical outcomes in the GEMINI 2 trial confirm and extend the previously published 12-month data from the original GEMINI trial.
In the original GEMINI study, at 12 months, OMNI plus cataract surgery achieved a mean IOP reduction of 8.2 mmHg (-34%).

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Retrieved on:

Tuesday, November 14, 2023

Biotechnology, Genetics, Health, Cardiology, APOLLO, GEMINI, Research, AstraZeneca, Therapy, Patient, United States Treasury security, Polycythemia, ASCVD, Thalassemia, Moyamoya disease, Pharmaceutical industry, Cryptocurrency, Mallinckrodt, Silence

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Key Points:

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
“This has been a year of strong execution across Silence,” said Craig Tooman, President and CEO at Silence.
Revenue recognized for the quarter ending September 30, 2023 was £2.8 million, compared to £3.4 million for the quarter ending September 30, 2022.
As of September 30, 2023, the Company had £58.8 million of cash and cash equivalents and U.S. Treasury Bills, or approximately $71.7 million.

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Retrieved on:

Tuesday, November 7, 2023

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.

Key Points:

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
On October 26, 2023, WPS Government Health Administrators (“WPS”), a Medicare Administrative Contractor (“MAC”), published an LCD with an effective date of December 24, 2023.
Sight Sciences' management team will host a conference call today, November 7, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Silence Therapeutics Reports Second Quarter 2023 Results

Retrieved on:

Wednesday, August 16, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.

Key Points:

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.
“Silence’s strong second quarter results reflect continued execution and meaningful pipeline progress,” said Craig Tooman, President and Chief Executive Officer at Silence.
We remain on-track to report topline data in the fourth quarter of 2023.
Revenue recognized for the quarter ending June 30, 2023 was £9.1 million, compared to £3.6 million for the quarter ending June 30, 2022.

DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics's Platform

Retrieved on:

Thursday, July 27, 2023

DNA, Nucleic acid thermodynamics, PALO, DELFI, Cancer, Lung cancer, Deletion, Carcinoma, Non-small-cell lung cancer, Doctor of Philosophy, Whole genome sequencing, MD, Algorithm, AUC, Entrepreneurship, GEMINI, Incidence, Medical imaging, Nature Genetics

Now, for the first time, researchers have achieved genome-wide detection of tumor-specific mutations from the same low-coverage whole genome sequencing methods that form the basis of the DELFI Diagnostics platform.

Key Points:

Now, for the first time, researchers have achieved genome-wide detection of tumor-specific mutations from the same low-coverage whole genome sequencing methods that form the basis of the DELFI Diagnostics platform.
The combined technology also showed high performance in other applications including monitoring response to therapy, and distinguishing small-cell lung cancer from non-small cell lung cancer.
"We founded DELFI Diagnostics to address population-health needs in cancer detection with low-cost, flexibly deployable technology," said Nicholas Dracopoli, PhD, DELFI Diagnostics's Chief Scientific Officer and Co-Founder.
"We have already shown that this platform can detect lung cancer with very high sensitivity," said Peter Bach, MD, DELFI Diagnostics's Chief Medical Officer.